INmune Bio (NASDAQ:INMB) Stock Rating Upgraded by RODMAN&RENSHAW

INmune Bio (NASDAQ:INMB) was upgraded by investment analysts at RODMAN&RENSHAW to a “strong-buy” rating in a report released on Tuesday,Zacks.com reports.

A number of other research firms have also weighed in on INMB. Alliance Global Partners initiated coverage on shares of INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 price objective on the stock. Rodman & Renshaw initiated coverage on INmune Bio in a research note on Tuesday. They set a “buy” rating and a $23.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $20.75.

INmune Bio Price Performance

Shares of NASDAQ INMB opened at $9.06 on Tuesday. INmune Bio has a 1 year low of $4.32 and a 1 year high of $14.74. The firm has a market cap of $200.86 million, a PE ratio of -4.16 and a beta of 1.78. The company has a 50 day simple moving average of $5.54 and a 200 day simple moving average of $6.06.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings data on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.11). During the same period in the prior year, the business posted ($0.48) EPS. As a group, research analysts anticipate that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Financial Advocates Investment Management lifted its holdings in shares of INmune Bio by 14.8% during the fourth quarter. Financial Advocates Investment Management now owns 15,500 shares of the company’s stock valued at $72,000 after purchasing an additional 2,000 shares in the last quarter. Jane Street Group LLC purchased a new position in INmune Bio during the third quarter valued at $79,000. Sanctuary Advisors LLC bought a new position in shares of INmune Bio during the 3rd quarter valued at approximately $113,000. Barclays PLC boosted its position in shares of INmune Bio by 601.9% in the third quarter. Barclays PLC now owns 29,044 shares of the company’s stock worth $157,000 after purchasing an additional 24,906 shares during the period. Finally, Fermata Advisors LLC increased its stake in INmune Bio by 10.0% in the 4th quarter. Fermata Advisors LLC now owns 46,997 shares of the company’s stock worth $219,000 after buying an additional 4,267 shares in the last quarter. Hedge funds and other institutional investors own 12.72% of the company’s stock.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.